Related Experiment Video
Updated: Jun 26, 2025
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
PKIB, a Novel Target for Cancer Therapy
Anna Musket1,2, Jonathan P Moorman1,2,3, Jinyu Zhang1,2
1Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.
International Journal of Molecular Sciences
|May 11, 2024
Summary
Protein kinase A inhibitor β (PKIB) influences cancer cell behavior and prognosis. Further research into PKIB
Area of Science:
- Molecular Biology
- Oncology
- Cellular Signaling
Background:
- Protein Kinase A (PKA) is a crucial cAMP-dependent enzyme regulating cellular processes.
- Protein Kinase Inhibitor β (PKIB) is an endogenous inhibitor of PKA, with its precise role still under investigation.
- PKIB expression is linked to hormonal signaling and negatively correlates with cancer patient prognosis.
Purpose of the Study:
- To review the current literature on PKIB, focusing on its role in cancer development.
- To explore the potential of PKIB as a therapeutic target in oncology.
- To summarize PKIB's impact on cancer cell behavior via transcriptional regulation and AKT signaling.
Main Methods:
- Literature review of existing studies on PKIB.
- Analysis of genetic regulation and hormonal signaling pathways affecting PKIB expression.
- Examination of PKIB's mechanisms in modulating cancer cell functions.
Main Results:
- Increased PKIB expression is associated with poorer cancer patient prognosis.
- PKIB influences cancer cell behavior through nuclear transcriptional modulation.
- PKIB regulates oncogenic AKT signaling pathways, contributing to cancer progression.
Conclusions:
- PKIB exhibits oncogenic potential and plays a significant role in various cancers.
- Understanding PKIB's function is critical for developing novel cancer therapies.
- Further research is warranted to fully elucidate PKIB's role in both cancerous and non-cancerous diseases.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:27Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
02:15M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K